Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP

Journal of Clinical Investigation

Volumn 100, Issue 10, 1997, Pages 2580-2587

  Soff, Gerald A ^a   Cornwell, Trudy L ^b   Cundiff, Deborah L ^a   Gately, Stephen ^a   Lincoln, Thomas M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cyclic GMP; Cyclic GMP dependent protein kinases; Drug tolerance; Nitroglycerin; Vascular smooth muscle

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; 8 BROMO CYCLIC GMP; BUCLADESINE; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DERIVATIVE; GLYCERYL TRINITRATE; THEOPHYLLINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CATTLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASODILATATION;

EID: 0030734036     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119801     Document Type: Article

References (51)

1. Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012.
2. Lincoln, T.M., and T.L. Cornwell. 1993. Intracellular cyclic GMP receptor proteins. FASEB (Fed. Am. Soc. Exp. Biol.) J. 7:328-338.
3. Nathan, C., and Q.-W. Xie. 1994. Nitric oxide synthases: roles, tolls, and controls. Cell. 78:915-918.
4. Radomski, M.W., and S. Moncada. 1993. Regulation of vascular homeostasis by nitric oxide. Thomb. Haemostasis. 70:36-41.
5. Wolfe, L., S.H. Francis, and J.D. Corbin. 1989. Properties of a cGMP-dependent monomeric protein kinase from bovine aorta. J. Biol. Chem. 264: 4157-4162.
6. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA. 88:1197-1201.
7. Landgraf, W., P. Ruth, A. Keilbach, B. May, A. Welling, and F. Hofmann. 1992. Cyclic GMP-dependent protein kinase and smooth muscle relaxation. J. Cardiovasc. Pharmacol. 20(Suppl. 1):S18-S22.
8. Koga, T., Y. Yoshida, J.Q. Cai, M.O. Islam, and S. Imai. 1994. Purification and characterization of 240-kDa cGMP-dependent protein kinase substrate of vascular smooth muscle. Close resemblance to inositol 1,4,5-trisphosphate receptor. J. Biol. Chem. 269:11640-11647.
9. Komalavilas, P., and T.M. Lincoln. 1994. Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic GMP-dependent protein kinase. J. Biol. Chem. 269:8701-8707.
10. Archer, S.L., J.M. Huang, V. Hampl, D.P. Nelson, P.J. Shultz, and E.K. Weir. 1994. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 91:7583-7587.
11. Bolotina, V.M., S. Najibi, J.J. Palacino, P.J. Pagano, and R.A. Cohen. 1994. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 368:850-853.
12. Wernet, W., V. Flockerzi, and F. Hofmann. 1989. The cDNA of the two isoforms of bovine cGMP-dependent protein kinase. FEBS (Fed. Eur. Biol. Soc.) Lett. 251:191-196.
13. Francis, S.H., T.A. Woodford, L. Wolfe, and J.D. Corbin. 1988. Types I alpha and I beta isozymes of cGMP-dependent protein kinase: alternative mRNA splicing may produce different inhibitory domains. Second Messengers Phosphoproteins. 12:301-310.
14. Tamura, N., H. Itoh, Y. Ogawa, O. Nakagawa, M. Harada, T.-H. Chun, S. Suga, T. Yoshimasa, and K. Nakao. 1996. cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase. Hypertension (Dallas). 27: 552-557.
15. Gamm, D.M., S.H. Francis, T.P. Angelotti, J.D. Corbin, and M.D. Uhler. 1995. The type II isoform of cGMP-dependent protein kinase is dimeric and possesses regulatory and catalytic properties distinct from the type I isoforms. J. Biol. Chem. 270:27380-27388.
16. Markert, T., A.B. Vaandrager, S. Gambaryan, D. Pohler, C. Hausler, U. Walter, H.R. de Jonge, T. Jarchau, and S.M. Lohmann. 1995. Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator. J. Clin. Invest. 96:822-830.
17. Jarchau, T., C. Hausler, T. Markert, D. Pohler, J. Vanderkerckhove. H.R. De Jonge, S.M. Lohmann, and U. Walter. 1994. Cloning, expression, and in situ localization of rat intestinal cGMP-dependent protein kinase II. Proc. Natl. Acad. Sci. USA. 91:9426-9430.
18. Cornwell, T.L., G.A. Soff, A.E. Traynor, and T.M. Lincoln. 1994. Regulation of the expression of cyclic GMP-dependent protein kinase by cell density in vascular smooth muscle cells. J. Vasc. Res. 31:330-337.
19. Brown, K.E., R. Lawrence, and G.E. Sonenshein. 1991. Concerted modulation of alpha 1(XI) and alpha 2(V) collagen mRNAs in bovine vascular smooth muscle cells. J. Biol. Chem. 266:23268-23273.
20. Majors, A.K., and L.A. Ehrhart. 1992. Cell density and proliferation modulate collagen synthesis and procollagen mRNA levels in arterial smooth muscle cells. Exp. Cell Res. 200:168-174.
21. Rovner, A.S., R.A. Murphy, and G.K. Owens. 1986. Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells. J. Biol. Chem. 261:14740-14745.
22. Shirinsky, V.P., K.G. Birukov, V.E. Kotelliansky, M.A. Glukhova, E. Spanidis, J.D. Rogers, J.H. Campbell, and G.R. Campbell. 1991. Density-related expression of caldesmon and vinculin in cultured rabbit aortic smooth muscle cells. Exp. Cell Res. 194:186-189.
23. Soff, G.A., R.W. Jackman, and R.D. Rosenberg. 1991. Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood. 77:515-518.
24. Gunther, S., R.W. Alexander, W.J. Atkinson, and M.A Gimbrone, Jr. 1982. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J. Cell Biol. 92:289-298.
25. Smith, J.B., and T.A. Brock. 1983. Analysis of angiotensin stimulated sodium transport in cultured smooth muscle cells from rat aorta. J. Cell. Physiol. 114:284-290.
26. Traynor, A.E., D.L. Cundiff, and G.A. Soff. 1995. cAMP influence on transcription of thombomodulin and myogenic proteins in smooth muscle is dependent on de novo synthesis of a protein intermediate. J. Lab. Clin. Med. 126: 316-323.
27. Nevins, J. 1987. Isolation and analysis of nuclear RNA. In Methods in Enzymology: Guide to Molecular Cloning Techniques. S. Berger and A. Kimmel, editors. Academic Press Inc., San Diego. 234-241.
28. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
29. - transport by heatstable enterotoxin: activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 263:C607-C615.
30. Cornwell, T.L., E. Arnold, N.J. Boerth, and T.M. Lincoln. 1994. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 267:C1405-C1413.
31. Ohara, O., T. Nakano, H. Teraoka, and H. Arita. 1991. cAMP negatively regulates mRNA levels of actin and tropomyosin in rat cultured vascular SMC. J. Biochem. 109:834-839.
32. Jiang, H., J.B. Shabb, and J.D. Corbin. 1992. Cross-activation: overriding cAMP/cGMP selectivities of protein kinases in tissues. Biochem. Cell Biol. 70:1283-1289.
33. 2+ induced by atrial natriuretic hormone, S-nitroso-N-acetylpenicillamine and 8-bromo cyclic GMP in cultured rat mesangial cells. Biochem. J. 274:323-328.
34. Colditz, G.A., K.T. Halvorsen, and S.Z. Goldhaber. 1988. Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am. Heart J. 116:174-180.
35. Parker, J.O. 1989. Intermittent transdermal nitroglycerin therapy in the treatment of chonic stable angina. J. Am. Coll. Cardiol. 13:794-795.
36. Thadani, U., H.L. Fung, A.C. Darke, and J.O. Parker. 1982. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am. J. Cardiol. 49: 411-419.
37. Bassan, M.M. 1990. The daylong pattern of the antianginal effect of long-term thee times daily administered isosorbide dinitrate. J. Am. Coll. Cardiol. 16:936-940.
38. May, D.C., J.J. Popma, W.H. Black, S. Schaefer, H. Lee, B.D. Levine, and L.D. Hillis. 1987. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N. Engl. J. Med. 317:805-809.
39. Horowitz, J.D., E.M. Antman, B.H. Lorell, W.H. Barry, and T.N. Smith. 1983. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation. 68:1247-1253.
40. Torresi, J., J.D. Horowitz, and G.J. Dusting. 1985. Prevention and reversal of tolerance to nitroglycerin with N-acetylcysteine. J. Cardiovasc. Pharmacol. 7:777-783.
41. Packer, M., W.H. Lee, P.D. Kessler, S.S. Gottlieb, N. Medina, and M. Yushak. 1987. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N. Engl. J. Med. 17:799-804.
42. Levy, W.S., R.J. Katz, R.L. Ruffalo, R.H. Leiboff, and A.G. Wasserman. 1988. Potentiation of the hemodynamic effects of acutely administered nitroglycerin by methionine. Circulation. 78:640-645.
43. Scharfstein, J.S., J.F. Keaney, Jr., A. Slivka, G.N. Welch, J.A. Vita, J.S. Stamler, and J. Loscalzo. 1994. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J. Clin. Invest. 94: 1432-1439.
44. Parker, J.O., B. Farrell, K.A. Labey, and B.F. Rose. 1987. Nitrate tolerance: the lack of effect of N-acetylcysteine. Circulation. 76:572-576.
45. Munzel, T., J. Holtz, A. Mulsch, D.J. Stewart, and E. Bassenge. 1989. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation. 79:188-197.
46. Dupuis, J., G. Lalonde, R. Lemieux, and J.L. Rouleau. 1990. Tolerance to intravenous nitroglycerin in patients with congestive heart failure. Role of increased volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J. Am. Coll. Cardiol. 16:932-935.
47. Boesgaard, S., J. Aldershvile, H.E. Poulsen, S. Loft, M.E. Anderson, and A. Meister. 1994. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ. Res. 74:115-120.
48. Watanabe, H., M. Kakihana, S. Ohtsuka, T. Enomoto, K. Yasui, and Y. Sugishita. 1993. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation. 88:29-36.
49. Baines, C., R.S. Szwarc, and H.A. Ball. 1994. Parallel tolerance between platelet cyclic GMP and preload effects of nitroglycerin in anaesthetized minipigs. Br. J. Pharmacol. 113:334-335.
50. Wu, X.B., B. Brune, F. Von Appen, and V. Ullrich. 1993. Efflux of cyclic GMP from activated human platelets. Mol. Pharmacol. 43:564-568.
51. Bauer, J.A., H.L. Fung, W. Zheng, Y. W. Kwon, M. Gopalakrishnan, and D.J. Triggle. 1993. Continuous versus intermittent nitroglycerin administration in experimental heart failure: vascular relaxation and radioligand binding to adrenoceptors and ion channels. J. Cardiovasc. Pharmacol. 22:600-608.